G-CSF prevents the suppression of bone marrow hematopoiesis induced by IL-12 and augments is antitumor activity in a melanoma model in mice

J. Gołab, T. Stokłosa, R. Zagozdzon, A. Kaca, Adam Giermasz, Z. Pojda, E. Machaj, A. Dabrowska, W. Feleszko, W. Lasek, A. Iwan-Osiecka, M. Jakóbisiak

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Background: IL-12 has been successfully used in experimental tumor therapy. However, administration of this cytokine induces dose-dependent suppression of hematopoiesis that could potentially limit its use in clinical trials. We decided to examine whether the myelosuppressive activity of IL-12 could be corrected by the administration of G-CSF. Materials and methods: In the initial experiments the influence of IL-12 and/or G-CSF on bone marrow and spleen GM-CFC was evaluated. To examine whether G-CSF could influence the antitumor activity of IL-12 the combination therapy with these agents was carried out starting on day seven following inoculation of melanoma MmB16 cells into the footpads of B6D2F1 mice. To obtain insight into the mechanism of the observed augmented antitumor activity of the combination therapy with IL-12 and G-CSF, the influence of these cytokines on macrophage activity (cytotoxicity and nitric oxide release) was analyzed. Results: In accord with our expectations, the application of G-CSF partially prevented the suppression of bone marrow myelopoiesis in IL-12-treated mice. Unexpectedly, G-CSF also showed potentiation of antitumor effects of IL-12 in this mechanoma model. The augmented antitumor activity of combined IL-12/G-CSF immunotherapy could result from the enhanced stimulation of macrophage NO production and cytotoxicity. Conclusion: The simultaneous administration of IL-12 and G-CSF partially prevented suppression of bone marrow myelopoiesis in IL-12-treated mice. Moreover, treatment with these cytokines also results in potentiated antitumor effects in a murine melanoma model.

Original languageEnglish (US)
Pages (from-to)63-69
Number of pages7
JournalAnnals of Oncology
Volume9
Issue number1
DOIs
StatePublished - Jan 1998
Externally publishedYes

Fingerprint

Hematopoiesis
Granulocyte Colony-Stimulating Factor
Interleukin-12
Melanoma
Bone Marrow
Myelopoiesis
Cytokines
Macrophages
Investigational Therapies
Immunotherapy
Nitric Oxide
Therapeutics
Spleen
Clinical Trials

Keywords

  • Granulocyte colony-stimulating factor
  • Interleukin-12
  • Melanoma

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

G-CSF prevents the suppression of bone marrow hematopoiesis induced by IL-12 and augments is antitumor activity in a melanoma model in mice. / Gołab, J.; Stokłosa, T.; Zagozdzon, R.; Kaca, A.; Giermasz, Adam; Pojda, Z.; Machaj, E.; Dabrowska, A.; Feleszko, W.; Lasek, W.; Iwan-Osiecka, A.; Jakóbisiak, M.

In: Annals of Oncology, Vol. 9, No. 1, 01.1998, p. 63-69.

Research output: Contribution to journalArticle

Gołab, J, Stokłosa, T, Zagozdzon, R, Kaca, A, Giermasz, A, Pojda, Z, Machaj, E, Dabrowska, A, Feleszko, W, Lasek, W, Iwan-Osiecka, A & Jakóbisiak, M 1998, 'G-CSF prevents the suppression of bone marrow hematopoiesis induced by IL-12 and augments is antitumor activity in a melanoma model in mice', Annals of Oncology, vol. 9, no. 1, pp. 63-69. https://doi.org/10.1023/A:1008266321552
Gołab, J. ; Stokłosa, T. ; Zagozdzon, R. ; Kaca, A. ; Giermasz, Adam ; Pojda, Z. ; Machaj, E. ; Dabrowska, A. ; Feleszko, W. ; Lasek, W. ; Iwan-Osiecka, A. ; Jakóbisiak, M. / G-CSF prevents the suppression of bone marrow hematopoiesis induced by IL-12 and augments is antitumor activity in a melanoma model in mice. In: Annals of Oncology. 1998 ; Vol. 9, No. 1. pp. 63-69.
@article{6c0c315bd0954dd683db9b2b064156fd,
title = "G-CSF prevents the suppression of bone marrow hematopoiesis induced by IL-12 and augments is antitumor activity in a melanoma model in mice",
abstract = "Background: IL-12 has been successfully used in experimental tumor therapy. However, administration of this cytokine induces dose-dependent suppression of hematopoiesis that could potentially limit its use in clinical trials. We decided to examine whether the myelosuppressive activity of IL-12 could be corrected by the administration of G-CSF. Materials and methods: In the initial experiments the influence of IL-12 and/or G-CSF on bone marrow and spleen GM-CFC was evaluated. To examine whether G-CSF could influence the antitumor activity of IL-12 the combination therapy with these agents was carried out starting on day seven following inoculation of melanoma MmB16 cells into the footpads of B6D2F1 mice. To obtain insight into the mechanism of the observed augmented antitumor activity of the combination therapy with IL-12 and G-CSF, the influence of these cytokines on macrophage activity (cytotoxicity and nitric oxide release) was analyzed. Results: In accord with our expectations, the application of G-CSF partially prevented the suppression of bone marrow myelopoiesis in IL-12-treated mice. Unexpectedly, G-CSF also showed potentiation of antitumor effects of IL-12 in this mechanoma model. The augmented antitumor activity of combined IL-12/G-CSF immunotherapy could result from the enhanced stimulation of macrophage NO production and cytotoxicity. Conclusion: The simultaneous administration of IL-12 and G-CSF partially prevented suppression of bone marrow myelopoiesis in IL-12-treated mice. Moreover, treatment with these cytokines also results in potentiated antitumor effects in a murine melanoma model.",
keywords = "Granulocyte colony-stimulating factor, Interleukin-12, Melanoma",
author = "J. Gołab and T. Stokłosa and R. Zagozdzon and A. Kaca and Adam Giermasz and Z. Pojda and E. Machaj and A. Dabrowska and W. Feleszko and W. Lasek and A. Iwan-Osiecka and M. Jak{\'o}bisiak",
year = "1998",
month = "1",
doi = "10.1023/A:1008266321552",
language = "English (US)",
volume = "9",
pages = "63--69",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - G-CSF prevents the suppression of bone marrow hematopoiesis induced by IL-12 and augments is antitumor activity in a melanoma model in mice

AU - Gołab, J.

AU - Stokłosa, T.

AU - Zagozdzon, R.

AU - Kaca, A.

AU - Giermasz, Adam

AU - Pojda, Z.

AU - Machaj, E.

AU - Dabrowska, A.

AU - Feleszko, W.

AU - Lasek, W.

AU - Iwan-Osiecka, A.

AU - Jakóbisiak, M.

PY - 1998/1

Y1 - 1998/1

N2 - Background: IL-12 has been successfully used in experimental tumor therapy. However, administration of this cytokine induces dose-dependent suppression of hematopoiesis that could potentially limit its use in clinical trials. We decided to examine whether the myelosuppressive activity of IL-12 could be corrected by the administration of G-CSF. Materials and methods: In the initial experiments the influence of IL-12 and/or G-CSF on bone marrow and spleen GM-CFC was evaluated. To examine whether G-CSF could influence the antitumor activity of IL-12 the combination therapy with these agents was carried out starting on day seven following inoculation of melanoma MmB16 cells into the footpads of B6D2F1 mice. To obtain insight into the mechanism of the observed augmented antitumor activity of the combination therapy with IL-12 and G-CSF, the influence of these cytokines on macrophage activity (cytotoxicity and nitric oxide release) was analyzed. Results: In accord with our expectations, the application of G-CSF partially prevented the suppression of bone marrow myelopoiesis in IL-12-treated mice. Unexpectedly, G-CSF also showed potentiation of antitumor effects of IL-12 in this mechanoma model. The augmented antitumor activity of combined IL-12/G-CSF immunotherapy could result from the enhanced stimulation of macrophage NO production and cytotoxicity. Conclusion: The simultaneous administration of IL-12 and G-CSF partially prevented suppression of bone marrow myelopoiesis in IL-12-treated mice. Moreover, treatment with these cytokines also results in potentiated antitumor effects in a murine melanoma model.

AB - Background: IL-12 has been successfully used in experimental tumor therapy. However, administration of this cytokine induces dose-dependent suppression of hematopoiesis that could potentially limit its use in clinical trials. We decided to examine whether the myelosuppressive activity of IL-12 could be corrected by the administration of G-CSF. Materials and methods: In the initial experiments the influence of IL-12 and/or G-CSF on bone marrow and spleen GM-CFC was evaluated. To examine whether G-CSF could influence the antitumor activity of IL-12 the combination therapy with these agents was carried out starting on day seven following inoculation of melanoma MmB16 cells into the footpads of B6D2F1 mice. To obtain insight into the mechanism of the observed augmented antitumor activity of the combination therapy with IL-12 and G-CSF, the influence of these cytokines on macrophage activity (cytotoxicity and nitric oxide release) was analyzed. Results: In accord with our expectations, the application of G-CSF partially prevented the suppression of bone marrow myelopoiesis in IL-12-treated mice. Unexpectedly, G-CSF also showed potentiation of antitumor effects of IL-12 in this mechanoma model. The augmented antitumor activity of combined IL-12/G-CSF immunotherapy could result from the enhanced stimulation of macrophage NO production and cytotoxicity. Conclusion: The simultaneous administration of IL-12 and G-CSF partially prevented suppression of bone marrow myelopoiesis in IL-12-treated mice. Moreover, treatment with these cytokines also results in potentiated antitumor effects in a murine melanoma model.

KW - Granulocyte colony-stimulating factor

KW - Interleukin-12

KW - Melanoma

UR - http://www.scopus.com/inward/record.url?scp=6844259872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6844259872&partnerID=8YFLogxK

U2 - 10.1023/A:1008266321552

DO - 10.1023/A:1008266321552

M3 - Article

C2 - 9541685

AN - SCOPUS:6844259872

VL - 9

SP - 63

EP - 69

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 1

ER -